Cannabis Stocks Surge Amid Reports of Potential Federal Reclassification
Cannabis stocks experienced significant gains following reports that President Donald Trump is considering reclassifying marijuana to a less restrictive category.
Cannabis stocks experienced significant gains on Friday following reports that President Donald Trump is considering reclassifying marijuana as a Schedule III drug, a category that includes substances with moderate to low potential for dependence. This potential policy shift could reduce regulatory oversight and ease tax burdens for cannabis companies.
U.S.-listed shares of Tilray Brands surged 28%, while Canopy Growth and Aurora Cannabis saw increases of 20% and 15%, respectively.
According to a report from Bloomberg News, Trump has discussed the reclassification with marijuana industry executives, Health and Human Services Secretary Robert F. Kennedy Jr., and Centers for Medicare & Medicaid Services Administrator Mehmet Oz.
Analysts suggest that reclassifying marijuana could open the door for pharmaceutical companies to seek approval for more cannabis products, which could then be dispensed the same as other prescription drugs.
Currently, marijuana is classified as a Schedule I substance under the Controlled Substances Act, indicating a high potential for abuse and no accepted medical use. Reclassification to Schedule III would align it with drugs like Tylenol with codeine, potentially easing criminal penalties and reshaping the industry's federal standing.
The potential reclassification has been discussed in meetings with industry executives and key administration officials, signaling a possible shift in federal policy toward marijuana regulation.
Source
CNBCRelated News
Fact-checking
Fact-check the facts of the article using external sources and databases.